Octa-Arginine-Conjugated Liposomal Nimodipine Incorporated in a Temperature-Responsive Gel for Nasoencephalic Delivery
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Shuai Hong und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Yanbian University, Yanji 133002, Jilin, China. Hauptthemen laut MEDLINE: Nimodipine, Administration, Intranasal, Liposomes, Rats, Sprague-Dawley. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Department of Science and Technology of Jilin Province.
Abstract (Originalsprache)
Nimodipine is the primary clinical drug used to treat cerebral vasospasm following subarachnoid hemorrhage. Currently, tablets have low bioavailability when taken orally, and injections contain ethanol. Therefore, we investigated a new method of nimodipine administration, namely, nasoencephalic administration. Nasal administration of nimodipine was carried out by attaching the cell-penetrating peptide octa-arginine (R8) to liposomes of nimodipine and incorporating it into a temperature-sensitive in situ gel. The prepared liposomes and gels underwent separate evaluations for in vitro characterization. In vitro release exhibited a significant slow-release effect. In vitro toad maxillary cilia model, RPMI 2650 cytotoxicity, and in vivo SD rat pathological histotoxicity experiments showed that all the dosage from the groups had no significant toxicity to toad maxillary cilia, RPMI 2650 cells, and SD rat tissues and organs, and the cilia continued to oscillate up to 694 ± 10.15 min, with the survival rate of the cells being above 85%. A transwell nasal mucosa cell model and an isolated porcine nasal mucosa model were established, and the results showed that the osmolality of the R8-modified nimodipine liposomal gel to nasal mucosal cells and isolated porcine nasal mucosa was 30.41 ± 2.14 and 65.9 ± 7.34 μg/mL, respectively, which was significantly higher than that of the NM-Solution and PEGylated nimodipine liposome gel groups. Animal fluorescence imaging studies revealed that the R8-modified nimodipine liposomal gel displayed increased brain fluorescence intensity compared to the normal liposomal gel. Pharmacokinetic results showed that after transnasal administration, the AUC(0-∞) of the R8-modified nimodipine liposomal gel was 11.662 ± 1.97 μg·mL-1, which was significantly higher than that of the plain nimodipine liposomal gel (5.499 ± 2.89 μg·mL-1). Brain-targeting experiments showed that the brain-targeting efficiencies of the PEGylated nimodipine liposome gel and R8-modified PEGylated nimodipine liposome gels were 20.44 and 33.45, respectively, suggesting that R8/PEG/Lip-NM-TSG significantly increased the brain-targeting of the drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Yanbian University, Yanji 133002, Jilin, China.
- Central Laboratory of the Affiliated Hospital, Yanbian University, Yanji 133000, Jilin, China.
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji 133002, Jilin, China.
ORCID-Profile: Ming Guan Piao
Förderung
- Department of Science and Technology of Jilin Province
Zitieren
APA
Hong, S., Lin, C., Hu, J., Piao, J., & Piao, M. G. (2024). Octa-Arginine-Conjugated Liposomal Nimodipine Incorporated in a Temperature-Responsive Gel for Nasoencephalic Delivery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00634
Vancouver
Hong S, Lin C, Hu J, Piao J, Piao MG. Octa-Arginine-Conjugated Liposomal Nimodipine Incorporated in a Temperature-Responsive Gel for Nasoencephalic Delivery. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00634
BibTeX
@article{Hong2024,
author = {Hong, Shuai and Lin, Changxiu and Hu, Junsheng and Piao, Jingshu and Piao, Ming Guan},
title = {Octa-Arginine-Conjugated Liposomal Nimodipine Incorporated in a Temperature-Responsive Gel for Nasoencephalic Delivery},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00634}
}
EUVIMED